Navigation Links
Vessel in Medical Technology

vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

... Reduced Stenosis, Healthy Endothelial Regrowth in vessel Treated Proactively for Vulnerable Plaque ... mm vProtect(TM) Luminal Shield was placed in the vessel (reference vessel diameter 2.74 mm), resulting in a post-procedural ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... cell that controls tumor cell division and blood vessel growth - Phase III trials underway to ... cell that controls tumor cell division and blood vessel growth. Preclinical and clinical data have ... a central regulator of tumor cell division, blood vessel growth and cell metabolism. Afinitor is also ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... designed to improve deliverability and vessel support. The first patient was enrolled into the ... disease, and that at two years, the treated vessel was able to expand and contract, without being ... to restore blood flow by propping a clogged vessel open, and to provide support until the ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... bioabsorbable drug eluting stent leaves behind a vessel that expands and contracts in a manner similar to a vessel that has never been stented, which could be an ... device has the potential to provide optimal vessel scaffolding and drug delivery capability over the ...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

... from the global, multi-center TAXUS ATLAS Small vessel (SV) and Long Lesion (LL) studies, designed to ... They reported a significant reduction in small vessel in-stent restenosis and major adverse coronary ... "We are pleased to have a second-generation small vessel DES and the U.S. market's first long DES under ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... a 32 percent reduction in the risk of target vessel failure (TVF, cardiac events related to the ... outcomes defined as cardiac death, MI or target vessel revascularization (TVR). -- A 40 percent ... Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. ...

Exercise Helps Prevent Age-Related Brain Changes in Older Adults

... cognitive decline in the elderly. The blood vessel and flow differences may be one reason." ... for shape and size. They then compared the blood vessel characteristics and how they related to blood ... a novel 3-D computer modeling system to analyze vessel characteristics. Note: Copies of RSNA ...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

... superiority to TAXUS in the endpoints of target vessel failure (TVF) and major adverse cardiac events ... reduction in the risk of ischemia-driven Target vessel Failure (TVF, cardiac events related to ... attack (myocardial infarction or MI) or target vessel revascularization (TVR). -- A clinically ...

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

... the TAXUS ATLAS Workhorse, Direct Stenting, Small vessel and Long Lesion trials were presented at the ... was reported at nine months, the overall target vessel revascularization (TVR) rate through three years ... said Dr. Turco. TAXUS Atlas Small vessel and Long Lesion Two-year data from the TAXUS ...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

... -- TAXUS ATLAS Workhorse, Direct Stenting, Small vessel and Long Lesion studies. Three-year data from the ... two-year data from the TAXUS ATLAS Small vessel and Long Lesion studies will be presented by John ... Vessels and Long Lesions in the TAXUS ATLAS SMALL vessel and TAXUS ATLAS LONG LESION Trials". TAXUS ATLAS ...

September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging

... vision. Severe Headache Could Signal Blood vessel Inflammation ROCHESTER, Minn. -- Severe and ... It also may include a biopsy of an affected blood vessel or tissue. Treatment depends on the type of ... applications under development are mapping blood vessel flow within organs and visualizing clogged ...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

... to complex patients with left main and three vessel disease treated with drug- eluting stents (DES)," ... to CABG in patients with left main and/or three vessel disease. The presentation will be part of an ... in patients with left main or three vessel disease. In the U.S., the TAXUS Liberte Stent is ...

Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes

... impact on diabetes-related blood vessel dysfunction MCLEAN, Va., May 27 /PRNewswire/ -- ... have the potential to positively impact the blood vessel dysfunction associated with diabetes, suggests a ... experienced a 30 percent improvement in measured vessel function at the completion of a 30-day trial. ...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

... that controls tumor cell division and blood vessel growth - RAD001 is currently being studied in ... of tumor cell division and blood vessel growth in cancer cells. "This is the first ... tumor cell division, cell metabolism, and blood vessel growth. RAD001 is a once-daily oral therapy that ...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

... by clinically significant reductions in target vessel failure and MACE, XIENCE V demonstrated an even ... -- A 32 percent reduction in the risk of Target vessel Failure (TVF, cardiac events related to the ... (myocardial infarction or MI) or target vessel revascularization (TVR). -- A 40 percent ...

Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery

... randomized pivotal clinical trial comparing graft vessel connections made using the PAS-Port system to ... to consistently and reliably attach a graft vessel to the aorta, generally in about two minutes," ... with little or no injury to the bypass graft vessel or the aorta. Importantly, the PAS-Port ...

Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent

... In-Segment Late Loss, Non-Inferiority in Target vessel Failure and Low Rates of MACE with XIENCE ... resulted in a significant 50 percent reduction in vessel renarrowing (in-segment late loss) at eight months, non-inferior rates of target vessel failure (TVF) at nine months, and an observed 42 ...

In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy

... restenosis, the hazardous narrowing of a blood vessel that often occurs despite the presence of a stent ... time the coating releases drugs meant to reduce vessel injury. Bare metal stents produce ... is released within 12 to 24 hours, after which vessel blockages regrow," said Levy. "In this study, the ...

VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation

... drug that targets inflammation in the blood vessel wall, a primary disease process in ... as well as medical imaging of the coronary vessel wall to evaluate impact on ... medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of ...

VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis

... and the buildup of plaque in arterial blood vessel walls. Research in both humans and mice has noted ... drug that targets inflammation in the blood vessel wall, a primary disease process ... oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of ...

VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome

... VIA-2291 targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis and ... drug that targets inflammation in the blood vessel wall, a primary disease process ... oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of ...

Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

... to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a ... offers a comprehensive portfolio of vessel closure, endovascular and coronary products that ...

Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions

... data from the pivotal TAXUS ATLAS Small vessel and Long Lesion studies, which evaluate the ... the U.S. in 2008." The TAXUS ATLAS Small vessel and Long Lesion studies are global, ... lesions in 411 patients at 24 sites. The Small vessel study was designed to evaluate the safety and ...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

... and continued non- inferior rates of target vessel failure (TVF) with XIENCE V compared to the ... to TAXUS. (In-segment late loss is a measure of vessel renarrowing). The SPIRIT III clinical trial of ... -- In the major secondary endpoint of Target vessel Failure (TVF), XIENCE V continued to ...

Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis

... evaluate whether renal artery stenting may reduce vessel renarrowing, thereby potentially reducing other ... is binary restenosis at nine months, a measure of vessel renarrowing. Secondary endpoints in the trial ... a measure of the need to retreat a diseased vessel that has renarrowed. About the Investigational ...

Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results

... cardiac events (MACEs) reported that may possibly be related to target vessel revascularization, four (33%) may have been related to the PAS-Port system ... in approximately two minutes, with little or no injury to the bypass graft vessel or the aorta. As of March 31, 2009, almost 14,000 PAS-Port systems had ...

Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients

... and services of Guidant Cardiac Surgery and the VASOVIEW endoscopic vessel harvesting system. The creation of this new organization enables MAQUET ... comprehensive array of patient care solutions for less-invasive endoscopic vessel harvesting, off- and on-pump coronary artery bypass surgery and vascular ...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

... The EPIC Stent is a self-expanding nitinol stent designed to sustain vessel patency (openness), while providing enhanced visibility during placement. ... (MI, or heart attack) occurring during related hospitalization, target vessel revascularization (TVR) through nine months and amputation of the treated ...

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

... treatment of stenotic or occluded vessels, doctors widen the narrowed vessel using an angioplasty balloon catheter. In some cases, a stent, which is a metal scaffold, is then placed to hold the vessel open. However, these treatments may have limited effectiveness since, for ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... mm for XIENCE V vs. 0.36 mm for TAXUS). In-stent late loss is a measure of vessel re-narrowing. About XIENCE V XIENCE V is used to treat coronary ... Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. About Abbott Abbott ...

Chemoembolization Improving as Liver Cancer Treatment

... size of the beads themselves so that they can more fully block the blood vessel and further guard against potential leakage of blood that could feed the ... Hospital and Medical Center. "The more isolated the tumor and its blood vessel feeders, the better the chance for a complete cure." Improvements in ...

OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications

... and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical ... level -- accelerating cellular-cased biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at ...

Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent

... at nine months. A second parallel study named the TAXUS PERSEUS Small vessel study will compare the TAXUS Element Stent to a historic control (TAXUS V ... from 2.25 up to 2.75 millimeters. The primary endpoint of the small vessel study is in-stent late loss at nine months, and its secondary endpoint is ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... for this debilitating, rapidly progressive and incurable blood vessel disease -- Imatinib mesylate, available as Gleevec(R) for treatment of ... of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed ... a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its ...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

... the mTOR protein, a central regulator of cell division and tumor blood vessel growth. Data suggest RAD001 has clinical activity as a single agent or in ... as a central regulator of tumor cell division, cell metabolism and blood vessel growth. If approved, RAD001 will become the first oral, once-daily therapy ...

Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study

... Pre-Clinical Data Shows Increased Muscle and Blood vessel Formation in Animals' Hearts SUNRISE, Fla., ... that myoblasts expressing SDF-1 resulted in increased muscle and blood vessel formation in the damaged areas of the hearts, which was not observed in ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed ... a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its ...

Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms

... wide openings, called "necks." Aneurysms form when a weakness in a blood vessel wall causes the vessel to balloon out and form a thin-walled, blood-filled pouch. If this pouch, or sac, develops in a brain blood vessel and bursts, a patient can sustain a devastating, even lethal, stroke as ...

Cardica to Host Investor Briefing on 'Revolutionizing Revascularization'

... which are designed to allow surgeons to automate the attachment of blood vessel grafts during CABG procedures, replacing traditional hand-sewn sutures. ... in Atlanta. As previously announced, the trial, which compared graft vessel connections made using the PAS-Port system to conventional hand-sewn ...
Other Contents
(Date:9/29/2014)... culture, mathematics is often deemed inaccessible or esoteric. Yet ... important role in our daily lives and a decisive ... often behind the scenes. , UC Santa Barbara,s ... and an assistant professor of mechanical engineering, often works ... his recent research published in the Proceedings of ...
(Date:9/29/2014)... of dinosaurs, gigantic reptilesdistant relatives of modern crocodilesruled the ... and it was thought they didn,t much interact. But ... researcher in the thigh of one of these ancient ... an earth and planetary sciences lecturer, and her Virginia ... bite marks in the thigh bones of an old ...
(Date:9/29/2014)... , Canda, September 29, 2014 ... as UID Coupled with Increasing Security Concerns Continue ... India is one of ... increasing adoption of biometrics systems, majorly in various ... NREGA, etc. Fingerprint modality based biometrics dominates the ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Tooth serves as evidence of 220 million-year-old attack 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
(Date:9/30/2014)... For millions of overweight Americans, regular exercise remains a ... type 2 diabetes. However, a new study suggests ... for others, depending on their genes. "While physical ... as effective for everyone when it comes to preventing ... Ruth Loos, director of the Genetics of Obesity and ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
(Date:9/30/2014)... AxoGen, Inc. (NASDAQ: AXGN), a leading ... market, announced the presentation of clinical data for Avance® ... of the Hand (ASSH) 2014 Annual Meeting which took ... The ASSH Best Paper Award was given to ”Functional ... Large Gap Nerve Discontinuities: Outcomes From a National Registry ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 During ... on natural approaches to health including achieving hormonal ... nutrient deficiencies and detoxification. , ... follows: , Date: October 6-9, 2014, Location: Online ... register: http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 ... private insurance exchanges within three years, profoundly impacting health ... pleased to announce its upcoming virtual conference, “Private ... offer a valuable lesson on where private health insurance ... the industry is expected to look like when they ...
Breaking Medicine News(10 mins):Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:New Atlantic Information Services Virtual Conference Will Detail Private Exchange Strategies for Health Plans 2
Other TagsOther Tags